NIKKEI 225
39,154.20 +349.55 (+0.90%) HANG SENG
18,117.45 +89.74 (+0.50%) CRUDE OIL
81.68 +0.05 (+0.06%) GOLD FUTURES
2,337.60 -6.80 (-0.29%) DOW
39,411.21 +260.91 (+0.67%) Bitcoin GBP
48,041.33 -1,049.64 (-2.14%)
PODD Dec 2024 180.000 call
- Bloomberg
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks
(Bloomberg) -- The new class of weight-loss drugs being tested as cure-alls for everything from knee replacements to liver disease keeps throwing corners of the stock market into disarray.Most Read from BloombergBuzzFeed Struggles to Sell Owner of Hit YouTube Show ‘Hot Ones’Jain Global Raises $5.3 Billion, Secures Cash From Abu DhabiNvidia’s 13% Stock Rout Has Traders Scouring Charts for SupportHow Long Can High Rates Last? Bond Markets Say Maybe ForeverTech Hits Stocks as Nvidia Extends Selloff
- Zacks
Insulet's (PODD) Omnipod 5 Favored in Study for Type 2 Diabetes
Insulet (PODD) reports positive findings from the SECURE-T2D pivotal trial, the largest study of AID therapy in people with type 2 diabetes.
- Business Wire
Insulet’s SECURE-T2D Pivotal Trial Results Demonstrate Omnipod® 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes
ACTON, Mass., June 21, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today shared positive results from its Omnipod 5 Automated Insulin Delivery System (Omnipod 5) type 2 diabetes pivotal trial at the American Diabetes Association (ADA) 84th Scientific Sessions in Orlando, Florida. This landmark study evaluated the impact of AID in a diverse group of people with type 2 diabetes who req
